The FDA said the recall was classified as the most serious Class 1 type, where there is a probability of serious health problems or death.» Read More
The Star-Ledger of New Jersey this weekend did a story that I think provides the best insight and backstory about what happened last week at the highest levels of Schering-Plough.CEO Fred Hassan was in Miami when doctors dropped the bomb on Vytorin and Zetia at the American College of Cardiology meeting.
CEO Fred Hassan updates investors on his company's plans to rebound from the Vytorin debacle.
Microsoft vs. Apple is just one of the exciting match-ups in this round of the Fast Money Madness tournament. Find out which companies make it to the Final Four.
Options activity is picking up in Johnson & Johnson stock. Why?
Somebody’s got to go. Find out who’s packing their bags and heading home in the Fast Money Madness tournament. In this round the traders slug it out in the Tech & Telecom and Health & Home sectors.
Ahead of the world's biggest gathering of cardiologists in Chicago this weekend, there's a flurry of news about stents--the expensive little wire mesh tubes that prop open clogged arteries. First, the Food and Drug Administration has posted new proposed guidelines for pre-and post-market testing of the controversial devices.
When it comes to the big business of celebrity gossip, a Hilton is cashing in, and I'm not talking Paris. I'm talking PEREZ, the self-dubbed 'Queen of Media.' Born Mario Lavandeira, Hilton named his persona after the ultimate celebrity who's famous for simply being famous, and created one of THE most successful celebrity gossip blogs.
As proxy statements pop up on www.sec.gov, investors can get a peek at who's making what. When you go to the web site, click on "Search for company filings," then click on "Companies and other filers," enter the ticker symbol, click on "Find companies" and then open up the "14A" or proxy statement.
"Do as I do, not as I say" That’s, the motto behind a little segment we like to call whale watching where we profile the world's most successful investors - a.k.a whales - and try to find out if you can trade in their wake.
Tuesday's explosive stock rally, fueled by the Fed's latest efforts to stem the credit crisis, is convincing more on Wall Street that the market may finally be nearing a bottom.
But not just for the environment. There’s a bull market here that investors shouldn’t miss.
Enthusiasm for the Federal Reserve's actions to stem the credit crunch propelled the Dow Jones Industrial Average to a higher close Monday, a day when everyone expected a rout due to weekend fire sale of Bear Stearns.
The Dow Jones Industrial Average pared its losses Monday as the sell-off spurred by the fire sale of Bear Stearns wasn't as bad as expected.
Q: On Fast Money’s trader radar we look at the stock that was lighting up screens across Wall Street. The current market is giving many investors headaches and as they reach for Tylenol, its maker may be the band-aid their portfolio needs. The largest health products company sells everything from Listerine mouthwash to artificial sweeteners and the stock popped today after FDA approved its new stents. Who is it?
Stocks plunged at the opening bell Monday as investors were spooked by the cash crisis at Bear Stearns that forced its sale for $2 a share to JP Morgan Chase.
Dow Industrials newcomer Bank of America leads the list as the highest current yielder of all 30 Dow stocks. Chevron, the other recent Dow addition enters the list with a 2.7% yield.
Scientists advising the Food and Drug Administration said anemia drugs sold by Amgen and Johnson & Johnson should be allowed to stay on the market for chemotherapy patients.
Stocks closed higher Thursday after Standard & Poor's delivered the words Wall Street was waiting to hear: The end is in sight.
Amgen, the world's biggest biotech company in terms of sales (Genentech dwarfs Amgen in market cap: $86 billion vs. $51 billion) and Dow component Johnson & Johnson avoided a worst-case scenario this afternoon.
Ahead of the big FDA Advisory Committee meeting tomorrow, Amgen held a quick conference call with some reporters this afternoon. The outside panel of experts will be deciding whether to recommend putting more restrictions on the use of the blockbuster drugs used to fight anemia in cancer patients getting chemo. For Johnson and Johnson and especially Amgen, the stakes are high.